Recruiting OBSERVATIONAL NCT05466786

Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer

Landscape Ofhomologous Recombination-related (HRR) Genes Mutations and HRD, and Correlation With Survival in HER2-lowbreast Cance

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Conditions Breast Cancer HER2-low Breast Cancer

Interventions Standard Management

Updated 5 times since 2022 Last updated: Sep 29, 2025 Started: Aug 7, 2022 Primary completion: May 31, 2027 Completion: May 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Breast Cancer and HER2-low Breast Cancer and is currently actively recruiting participants. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Nov 2025 — Present [monthly]

Recruiting
Oct 2025 — Nov 2025 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Oct 2025 [monthly]

Not Yet Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting
Sep 2022 — Jul 2024 [monthly]

Not Yet Recruiting

First recorded

Aug 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Data source: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China